MAPS PBC announces submission of a new drug application to the @US_FDA for MDMA-assisted therapy for PTSD. Read the full announcement here: https://t.co/PMum0QCcfj #PTSD #mentalhealth

A deep dive into neuropsychiatric therapeutics • Competitive landscape • Emerging treatments • Key concerns & more Exhibit 1: late-stage competitive landscape across key indications The global disease burden for these indications is immense, with >50M total patients &

Proud of Jerry & the ⁦@lifebiosciences⁩ team, working to reverse blindness 👏

Check out the January 2023 issue of Life Science Leader, including interviews with Verve Therapeutics founder and CEO Sekar Kathiresan and #CBER director Peter Marks. Happy New Year! https://t.co/BpO3G68Lzy

My thoughts on the impact of the Inflation Reduction Act’s Medicare “negotiation” provisions on #drug #innovation. #pricecontrols @LifeSciLeader1 @BenMComer https://t.co/D0zPT5V7k0

With a growing number of irons in the fire, the possibility for a #T1D cure is getting closer:

"What to expect at #BioFuture22: Join us for 600+ Life Sciences Leaders and Investors, 80+ Innovative Presenting Companies, Plenaries, Workshops, Networking Events, & One-to-One Meetings with Investors. Visit our website for more info! #BioFuture2022 https://t.co/wYXIIJfMuO"

I’ve not yet learned what will happen to GBT’s community outreach or the GBT Foundation after the Pfizer acquisition but will be keeping an eye on it. My column last April: Companies To Watch: Global Blood Therapeutics

From organ transplants to nutraceuticals: welcome to Dr. Ngoc Thai's new Uptown lab. https://t.co/j7362wPqJ0

THE SUPREME COURT HAS OVERTURNED ROE V. WADE, ELIMINATING THE CONSTITUTIONAL RIGHT TO ABORTION. https://t.co/ZNYRs3QnpJ

We had a wonderful time speaking with @BenMComer of @LifeSciLeader1 at #BIO2022! Looking forward to more conversations! @IAMBiotech #limitlesstogether

At #BIO2022 in San Diego. Finally back to “in-person” mode and meeting with @NPR @biotechnation @LifeSciLeader1 @BenMComer @NatureBiotech Lisa Melton and more! How I missed this! 😊

Semaglutide moves forward in obesity -- check out In Vivo's 'sema' brand spotlight (sub req.) on a drug with big ambitions, from obesity to NASH and Alzheimer's disease:

After Aducanumab: Finding New Treatments For Neurodegenerative Diseases https://t.co/yax6hySFgg

Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity

In a recent @demycolton virtual salon, industry experts discussed the “rapid growth” of women’s health, a traditionally “underserved” market.

In a move that shows you how much independence the FDA has these days....or not...they told me to reach out to WH in response to questions as to whether they signed off on an expanded access request for Trump to get $REGN antibody.

@BenMComer joins Melanie Senior, Harvard Pilgrim’s Michael Sherman, Boehringer Ingelheim’s Paolo Casarosa & Healogix CEO Harris Kaplan to explore how #COVID19 is driving changes in health delivery that impact biopharma (Tue 11am ET) #InformaCOVID19webevent

April is National @MinorityHealth Month. Failure to improve minority subgroup participation now will cost trial sponsors later, says @BenMComer: https://t.co/RQlM8mATkq #clinicaltrialdiversity #DiversityMatters

If you've got a sub to @PharmaPinkSheet check out this fun interactive timeline of FDA action milestones over the last decade by @brendasandburg and the design team.